Ponesimod: Dosage, Indications, Directions to Use, Warnings, and Side-Effects

Overview:

Ponesimod is a drug used for the management of multiple sclerosis (MS) that relapses. A chronic autoimmune condition called multiple sclerosis damages the central nervous system (CNS). The CNS's myelin, a layer of protection covering nerve fibers, is attacked by the immune system in MS, which results in inflammation and damage to the myelin and nerve fibers. This harmful action interferes with the brain's ability to communicate with the body's other parts, leading to a variety of symptoms, including fatigue, numbness, tingling, weakness, impaired vision, problems with balance and coordination, and cognitive impairment.

Ponesimod functions as a selective modulator of the sphingosine-1-phosphate receptor (S1P1), lowering blood lymphocyte (a type of white blood cell) levels and preventing them from entering the brain and spinal cord, where they can harm nerve cells.

Ponesimod was created in response to the demand for a more focused sphingosine 1-phosphate receptor modulator than Fingolimod. More specialized modulators were developed because it was thought that Fingolimod's action at the sphingosine 1-phosphate receptor was partially responsible for its side effects. The FDA (Food and Drug Administration) approved Ponesimod on March 18, 2021.

How Does Ponesimod Work?

1. The sphingosine-1-phosphate receptor 1 (S1P1) is a particular receptor type present on the surface of certain immune cells. Ponesimod functions by modulating its activity. By interacting with this receptor, Ponesimod stops immune cells from exiting lymph nodes and entering the circulation.

2. This is significant because, in MS, immune cells attack and damage the myelin sheath that envelops and safeguards the nerve fibers in the central nervous system. Ponesimod can reduce the number of immune cells that attack myelin and halt the progression of the illness by blocking immune cells from entering the brain.

3. As a selective S1P1 receptor modulator, Ponesimod only targets a certain kind of S1P receptor and does not impact other immune system cells.

4. This makes it a helpful alternative to other drugs that could have more extensive impacts on the immune system for MS patients searching for a therapy choice.

Available Dose and Dosage Forms of Ponesimod:

Ponesimod is a medication that can be taken orally as tablets.

There are two strengths of the tablets:

1. 10 milligrams (mg).

2. 20 mg.

For most individuals, a starting dose of 20 mg is given orally once daily.

Meals:

The pills can be taken with or without meals and should be taken as a whole with water. Based on the patient's reaction to therapy, as well as other variables, including medical history, age, weight, and other drugs being used, the prescribing healthcare professional may change the dosage.

Missed Dose:

It is important to take the medication as prescribed by the doctor. If any dose is missed, it must be taken as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed. It is crucial to follow the doctor's recommendations and report any side effects or concerns as soon as possible.

Warnings

It is critical to adhere to the instructions. Like any medicine, Ponesimod may have possible adverse effects and precautions that should be taken into account prior to using the drug.

Some significant cautions to be mindful of are as follows:

1. Heart Effects: Ponesimod may alter heart rate and rhythm, especially in the hours following the initial dosage. Because of this post-drug effect, it is advised that patients be observed for at least six hours following the initial dosage. Those having a history of cardiovascular illness or conduction issues should use Ponesimod with care.

2. Increased Risk of Infection: Ponesimod can have an adverse effect on the immune system and may raise infection risk, especially in people who have recently been sick. Patients should be monitored for infection symptoms as they may need to be treated with antibiotics or antiviral drugs.

3. Liver Function: Ponesimod may cause changes in liver function, including increases in liver enzyme levels. During therapy, liver function tests should be routinely checked.

4. Effects on the Respiratory System: Ponesimod may cause respiratory issues, including bronchitis and shortness of breath. Individuals with a history of respiratory issues need to be closely monitored.

For Patients:

What Should You Consider Before Starting Ponesimod?

Before starting Ponesimod, things to be considered include:

1. Medical History: All existing and past conditions, cardiovascular, respiratory, and all medications taken must be discussed with the doctor, as starting Ponesimod may cause adverse drug reactions or may not be suitable in certain medical conditions.

2. Pregnancy or During Nursing: Ponesimod should not be used during pregnancy or during nursing since it might damage the developing baby. Pregnant or potentially pregnant women should use an effective form of contraception while under Poesimod therapy. It is not advised to breastfeed while using Ponesimod since it is unknown whether the drug is excreted in human milk.

3. Heart Function: Ponesimod may alter heart rate and rhythm, especially in the hours following the initial dosage. Before beginning therapy, the healthcare practitioner may order tests to determine the heart's health and functioning. Blood pressure and heart rate will also be monitored at the first dosage and at regular intervals afterward.

4. Infections: Ponesimod's potential to impair the immune system increases the risk of infections. Before beginning therapy, the healthcare professional should be aware of any recent illnesses or infection-related symptoms.

Indications of Ponesimod:

The following conditions call for Ponesimod:

1. Treatment of Relapsing Forms of MS in Adults: This medication is licensed for the management of clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. For treating primary progressive MS, it is not used.

2. Relapse Prevention: Ponesimod reduces relapses in MS patients. According to clinical studies, Ponesimod can reduce the risk of recurrence by up to 30%.

3. Slowing the Progression of Impairment: It has been demonstrated that Ponesimod slows the progression of MS-related disability. This involves reducing the likelihood that a disability's symptoms, such as trouble walking, cognitive impairment, and other symptoms, will get worse.

4. Delaying the Accumulation of New Brain Lesions: Ponesimod has been shown to slow the development of new brain lesions in MS patients, thereby preventing their accumulation. Brain lesions, areas of inflammation and damage in the brain, can trigger MS symptoms.

Ponesimod is not a cure for MS, but it can help control symptoms and delay the disease's development, and it is crucial to remember that.

Things to Inform the Doctor Before Taking Ponesimod:

1. Any Allergies: The doctor should be informed if a person has ever experienced an adverse response to Ponesimod or allergies to any other drugs.

2. Other Health Issues: Other health issues, such as liver or kidney illness, cardiac issues, or infections, should be reported to the doctor. Ponesimod can have an adverse effect on the immune system.

3. Additional Medications: If an individual is taking any other drugs, including prescription, over-the-counter, and herbal supplements, they should be informed.

4. Vaccinations: Anyone receiving recent vaccinations or those scheduled while taking Ponesimod should be informed. Receiving some vaccinations while taking this medicine may not be safe.

5. Pregnancy or Nursing: Inform the doctor if you are expecting or nursing a baby. The doctor will need to determine whether the advantages of this drug outweigh the dangers before deciding whether to take it during pregnancy or while nursing.

6. Past Infections: If a person has ever had an infection, it should be reported to the doctor. Because Ponesimod might increase the risk of infections, the doctor may want to monitor for signs of infection.

Side Effects of Ponesimod:

Ponesimod's typical side effects include the following:

1. Headache.

2. Raised liver enzyme levels.

3. Infected respiratory tracts.

4. Higher blood pressure.

5. Backache.

6. Diarrhea.

7. Liver function tests are abnormal.

8. Infections of the urinary tract.

Serious side effects that are less frequent might include:

1. Macular swelling (swelling in the retina of the eye).

2. Increased likelihood of contracting infections, particularly dangerous ones like herpes zoster (shingles).

3. Increased likelihood of liver issues, such as liver failure.

4. Symptoms of allergic reactions include hives, a rash, breathing problems, and swelling of the face, lips, tongue, or neck.

How Should This Medicine Be Used?

1. Ensure meticulous adherence to the guidance provided by the healthcare provider when taking Ponesimod. Depending on individual factors, such as a patient's medical background, they will suggest an appropriate frequency and dosage for effectiveness.

2. Ponesimod is typically taken once daily, with or without meals.

3. Take the pill whole with water. Avoid breaking, chewing, or crushing the pill.

4. If individuals forget, they should take the missed dose as soon as they remember. If the next dose is almost due, they can continue with the usual dosing plan and skip the missed dose. Do not take a double dose to make up for the skipped dose. Contact a healthcare provider if any adverse effects occur.

What Should Be Done to Treat Ponesimod Overdose?

Stabilize the person's vital signs, including respiration, blood pressure, and heart rate, as this is the top priority. Providing oxygen, water, and drugs to control blood pressure and heart rate are all primary measures of supportive care.

1. Decrease Absorption: If the overdose was recent, the medical professional could try to stop the body from absorbing as much Ponesimod by making the patient vomit or giving them activated charcoal. This helps limit the medication's further absorption.

2. Monitoring and Treating Symptoms: The healthcare professional may monitor the patient's symptoms and administer appropriate therapy. For instance, if the patient is having seizures or muscular spasms, medication may be prescribed to manage these symptoms.

3. Supportive Care: If the situation is serious, the patient may need to be admitted to the hospital for supportive care, which includes monitoring vital signs and providing additional treatments as needed.

In general, getting prompt medical help in the event of a Ponesimod overdose is the recommended course of action.

How to Store Ponesimod?

For Ponesimod to be effective and safe, it must be stored properly.

These are some general recommendations regarding Ponesimod storage:

1. Maintain Ponesimod in Its Original Packaging: Ponesimod should be kept in its original packaging with the cap securely fastened. This can help shield the drug from moisture and light.

2. Storage at Room Temperature: Ponesimod should be stored between 68°F (20 °C) and 77°F (25 °C) to remain well preserved. Avoid storing the drug in areas with extreme heat or cold, such as a freezer or a sunny window.

3. Keep Ponesimod Away From Children and Pets: Ponesimod drugs have to be kept in a safe place, like a locked cabinet or drawer, away from kids.

4. Do Not Use Medicine That Has Passed Its Expiration Date: Verify the drug's expiration date on the label and do not use Ponesimod beyond that time. If utilized, expired medication may not be beneficial and may even be harmful.

5. Do Not Transfer to Another Container: Transferring Ponesimod to another container, such as a pillbox or medicine organizer, is not advised. Confusion may result from this, which might result in unintentional overdose.

For Doctors:

Indications:

Ponesimod is used in adults with relapsing types, clinically isolated syndrome of multiple sclerosis (MS), relapsing-remitting disease, and active secondary progressive illness.

Dosage:

Ponesimod should be taken orally once daily at a dose of 20 mg. One can take Ponesimod with or without meals. The drug must be taken whole; it must not be chewed or mashed. A missing dosage should be taken as soon as feasible, the next day. The following dosage should be taken at the usual time if a dose is missed for the full day.

What is Ponesimod's Mechanism of Action?

Ponesimod works as an S1P1 receptor modulator. Lymphocyte migration is reduced following the use of this compound as an immunomodulator; it helps maintain a standing stock of lymphocytes in the lymphoid tissues, thereby reducing the absolute number of circulating lymphocytes. It also exerts anti-inflammatory effects by reducing the number of lymphocytes migrating into the CNS, thereby reducing neuroinflammation.

Pharmacokinetics

Increase dosage proportionally in the dose range examined after Ponesimod oral administration (1 to 75 milligrams). After three days of maintenance dosing with Ponesimod, steady-state levels are 2.0 to 2.6 times higher than after a single dose. With a 25 percent inter-subject variability across trials, the pharmacokinetics of Ponesimod are comparable in healthy persons and patients with multiple sclerosis.

Absorption

Ponesimod's plasma concentration reaches its peak within two to four hours after administration. A 10-milligram dose has an oral bioavailability of 84%.

Food Impact

Eating does not affect the pharmacokinetics of Ponesimod in a clinically significant way; hence, it can be given with or without meals.

Distribution

The steady-state volume of distribution of Ponesimod after IV treatment in healthy people is 160 L. Ponesimod is mostly distributed in the plasma fraction of whole blood (78.5%) and strongly bound to plasma proteins. According to animal studies, Ponesimod readily crosses the blood-brain barrier.

Metabolism

Ponesimod is digested in humans before excretion, even though the major circulating form of the drug in plasma was unaltered Ponesimod. M12 and M13, two inactive circulating metabolites, have also been found in human plasma. M13 and M12 account for 20 percent and 6 percent, respectively, of all drug exposure. When Ponesimod is administered at the prescribed levels, both metabolites are inactive at S1P receptors.

Ponesimod is metabolized to M13 predominantly via a mixture of non-cytochrome P450 (CYP450) enzymatic activity, according to experiments with human liver preparations. Ponesimod is oxidized to M12 by a number of CYP450 (CYP2J2, CYP3A4, CYP3A5, CYP4F3A, and CYP4F12) and nonCYP450 enzymes. Ponesimod is furthermore directly glucuronidated.

Excretion

The overall clearance of Ponesimod following a single IV (intravenous) infusion is 3.8 L/hour. After oral administration, the elimination half-life is around 33 hours. A single oral dosage of 14C-Ponesimod recovered between 57 percent and 80 percent in feces (16 percent as unaltered Ponesimod) and 10 percent and 18 percent in urine (no unchanged Ponesimod).

Toxicity

Nonclinical Toxicity:

1. In experiments on animals, Ponesimod has been proven to elicit reversible reductions in heart rate. The drug's mode of action, which includes binding to S1P receptors on the heart muscle, is considered to be responsible for this impact.

2. Ponesimod was discovered to have impacts on the reproductive system in preclinical trials, including lower fertility in male rats and an increase in stillbirths in female rats. Nevertheless, no human research has shown evidence of these effects.

Clinical Toxicity:

1. In clinical tests, headache, elevated liver enzymes, and upper respiratory tract infections were Ponesimod's most frequent side effects.

2. Some individuals' heart rates have been proven to slow down after using Ponesimod, especially after the first dosage. This effect generally subsides quickly and is minor.

3. Ponesimod lowers the immune system by preventing immune cells from migrating to the central nervous system, which raises the risk of infections. Individuals receiving Ponesimod should be watched for any indications of infection, and if one does occur, therapy should be stopped.

4. Ponesimod can occasionally cause an allergic reaction, which can be fatal. Possible symptoms include rash, itching, breathing problems, and swelling of the face, lips, tongue, or throat. If these symptoms develop, individuals should seek prompt medical assistance.

Management of Toxicity:

The general approaches listed below can be utilized to control Ponesimod's toxicities:

1. Bradycardia: If bradycardia develops, it may be treated by monitoring the patient's blood pressure and heart rate. In order to raise the heart rate, it may occasionally be necessary to use drugs or other treatments.

2. Elevated Liver Enzyme Levels: The patient's liver function may need to be periodically checked if liver enzyme levels rise. In rare circumstances, Ponesimod dosage may need to be decreased.

3. Infections: Individuals using Ponesimod may be more prone to infections, so it is crucial to watch for early warning symptoms and treat any infections that do arise very far away.

4. Macular Edema: A patient who develops macular edema may need to visit an eye doctor for a diagnosis and potential therapy.

5. Additional Toxicities: Further therapies may be required depending on the individual toxicity. For instance, the patient might need to stop taking the medicine if fetal toxicity arises.

Contraindications to Ponesimod:

1. An allergy to Ponesimod or any of its ingredients.

2. Active diseases, such as hepatitis B or C, TB, or the human immunodeficiency virus (HIV).

3. Serious liver damage.

4. A recent myocardial infarction or severe, untreated hypertension.

5. The use of potent CYP2C8 inhibitors like Gemfibrozil.

It is crucial to remember that this is not an exhaustive list, and patients should always communicate with their physician about any new drug to discuss the potential dangers and advantages.

Drug Interactions of Ponesimod:

Ponesimod may interact with other drugs, which may reduce the effectiveness of the former or raise the possibility of negative side effects.

The following are some instances of medications and Ponesimod that may interact:

1. Medications That Block the CYP2C8 Enzyme: For example, Gemfibrozil may increase exposure to Ponesimod and raise the possibility of negative consequences.

2. Medications That Activate the CYP2C8 Enzyme: For example, Rifampin may reduce exposure to Ponesimod and lessen its effectiveness.

3. Concurrent Use of Other Immunosuppressive Medications: Such as Azathioprine or Cyclosporine, may raise the risk of infections and adverse immune system consequences.

4. Live Vaccinations: This may have an adverse effect on the immune system, and taking it at the same time as live vaccines may make an infection more likely.

5. Medications That Extend the QT Interval: When administered with Ponesimod, concurrent use of medicines that extend the QT interval, such as Amiodarone or Quinidine, may increase the risk of bradycardia.

6. Antihypertensive Medications: When administered with Ponesimod, concomitant use of hypertension medications, such as beta-blockers or calcium channel blockers, may increase the risk of bradycardia.

Other Specifications

Ponesimod in Pregnancy:

Ponesimod is a category C pregnancy medicine, which means that using it while pregnant carries certain potential risks for the developing fetus. When providing Ponesimod to expectant mothers, the drug's potential advantages and hazards for the fetus must be balanced. Ponesimod use during pregnancy has been linked to negative effects on fetal development in animals, including skeletal deformities and lower body weight. There are no sufficient or well-monitored studies on pregnant women.

Ponedimod During Breastfeeding and Contraception: Ponesimod is contraindicated during breastfeeding because it has unknown effects on the breastfeeding infant. Contraceptive measures are advocated during therapy and for one month after cessation of treatment because of possible teratogenic effects.

Ponesimod in Pediatrics:

Ponesimod is not yet licensed for use in children, and its use in pediatric patients has not been demonstrated. There is limited evidence on the use of Ponesimod in teenagers, and neither its safety nor efficacy has been evaluated in pediatric populations.